RONALD GRESS, M.D.
Osteopathic Medicine in Bethesda, MD

2004024, Dec 2, 2004

Feb 27, 2004

10/488196

Daniel Fowler - Bethesda MD, US
Jeanne Hou - Bethesda MD, US
Unsu Jung - Ashburn VA, US
Ronald Gress - Gaithersburg MD, US
Bruce Levine - Cherry Hill NJ, US
Carl June - Merion Station PA, US

A61K045/00, C12N005/08

424/093710, 435/372000

Methods are provided for producing a population of substantially purified CD4+ Th1 lymphocytes. The method includes stimulating a population of substantially purified CD4+ T cells isolated from a subject by contacting the population with an anti-CD3 monoclonal antibody and an antibody that specifically binds to a T cell costimulatory molecule in the presence of a Th1 supportive environment to form a stimulated population of T cells. The stimulated population of CD4+ T cells is allowed to proliferate in a Th1 supportive environment. In one example, the Th1 supportive environment includes at least 20 IU/ml of IL-2, for example about 1000 I.U./ml of IL-2, and a neutralizing amount of an IL-4, an IL-13, and/or an IL-4/IL-13 neutralizing agent. In other examples, the supportive environment further includes at least 1 ng/ml of IL-12, for example about 2.5 ng/ml of IL-12. Purified populations of Th1 cells are disclosed herein, as are methods for their use.

8075921, Dec 13, 2011

Mar 30, 2010

12/750374

Daniel H. Fowler - Bethesda MD, US
Unsu Jung - Ashburn VA, US
Ronald E. Gress - Gaithersburg MD, US
Bruce Levine - Cherry Hill NJ, US
Carl June - Merion Station PA, US

The United States of America as represented by the Secretary of the Deparment of Health and Human Services - Washington DC
The Trustees of the University of Pennsylvania - Philadelphia PA

A61K 35/28

424577

Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.

7718196, May 18, 2010

Dec 9, 2005

11/298313

Daniel H. Fowler - Bethesda MD, US
Unsu Jung - Ashburn VA, US
Ronald E. Gress - Gaithersburg MD, US
Bruce Levine - Cherry Hill NJ, US
Carl June - Merion Station PA, US

The United States of America, as represented by the Department of Health and Human Services - Washington DC
The Trustees of the University of Pennsylvania - Philadelphia PA

A61K 35/28, C12N 5/08

424578, 4353723

Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.

2009013, May 21, 2009

Sep 26, 2008

12/239466

FRANCIS A. FLOMERFELT - KENSINGTON MD, US
RONALD E. GRESS - GAITHERSBURG MD, US

A61K 39/395, A61K 31/7105, A61K 38/10, A61P 37/06, A61P 37/00

4241391, 514 44, 514 14

This disclosure provides methods useful for altering cell proliferation by modifying SPATIAL activity in cells. In some methods, thymocyte numbers in subjects with disease-associated immunodeficiencies are increased by administering an agent that inhibits SPATIAL activity. Also provided are methods useful for increasing thymocyte number in a subject by administering an agent that interferes with an interaction between SPATIAL and Uba3. In other methods, cell growth is inhibited by introducing or expressing a SPATIAL or SPATIAL-related polypeptide or nucleic acid in one or more cell(s), such as neoplastic cell(s). Further provided are methods of identifying agents that modify (for example, inhibit) SPATIAL expression or activity, or which interfere with an interaction between SPATIAL and Uba3 polypeptides, and therefore which are useful in influencing thymocyte number.

5344755, Sep 6, 1994

Jun 8, 1990

7/535407

Gene M. Shearer - Bethesda MD
Ronald E. Gress - Gaithersburg MD
Mario Clerici - Rockville MD
Philip J. Lucas - Silver Spring MD
Charles S. Via - Ellicott City MD

The United States of America as represented by the Department of Health
and Human Services - Washington DC

G01N 33569

435 5

A sensitive and accurate tissue culture system and kit for detecting subtle changes in immune function is provided. The system is based on the comparison of IL-2 production by T helper cells in response to recall antigens including influenza A virus, tatanus toxoid, alloantigens, mouse xenogeneic antigens and the like or combinations thereof. Different stages of immune dysfunction can be differentiated and organ graft rejection can be predicted by the method of the present invention.

2007024, Oct 25, 2007

Nov 18, 2003

10/579879

Francis Flomerfelt - Kensington MD, US
Ronald Gress - Gaithersburg MD, US

A61K 39/00, A61K 38/00, A61K 39/395, A61K 48/00, A61P 31/18, C12N 5/06, C12Q 1/68, G01N 33/00

424130100, 424184100, 435375000, 435006000, 436086000, 514002000, 514044000, 800003000

This disclosure provides methods useful for altering cell proliferation by modifying SPATIAL activity in cells. In some methods, thymocyte numbers in subjects with disease-associated immunodeficiencies are increased by administering an agent that inhibits SPATIAL activity. Also provided are methods useful for increasing thymocyte number in a subject by administering an agent that interferes with an interaction between SPATIAL and Uba3. In other methods, cell growth is inhibited by introducing or expressing a SPATIAL or SPATIAL-related polypeptide or nucleic acid in one or more cell(s), such as neoplastic cell(s). Further provided are methods of identifying agents that modify (for example, inhibit) SPATIAL expression or activity, or which interfere with an interaction between SPATIAL and Uba3 polypeptides, and therefore which are useful in influencing thymocyte number.

2004025, Dec 23, 2004

Apr 29, 2004

10/494540

Daniel Fowler - Bethesda MD, US
Unsu Jung - Ashburn VA, US
Jeffrey Medin - North York, CA
Ronald Gress - Gaithersburg MD, US
Andreas Erdmann - Washington DC, US
Bruce Levine - Cherry Hill NJ, US
Carl June - Merion Station PA, US

A61K045/00, A61K038/20

424/085200, 424/093710

A method is provided for producing a population of CD8 Tc1 and/or Tc2 lymphocytes ex vivo. The method includes stimulating a population of T cells obtained from a subject by contacting the population with an anti-CD3 monoclonal antibody and an antibody that specifically binds to a T cell costimulatory molecule in the presence of a Tc1 or Tc2 supportive environment to form a stimulated population of T cells. The stimulated population of CD8 T cells is allowed to proliferate in a Tc1 or Tc2 supportive environment. Purified populations of Tc1 and Tc2 cells are disclosed herein, as are methods for their use.

2004017, Sep 9, 2004

Dec 23, 2003

10/481913

Daniel Fowler - Bethesda MD, US
Jeanne Hou - Bethesda MD, US
Unsu Jung - Ashburn VA, US
Ronald Gress - Gaithersburg MD, US
Michael Bishop - Rockville MD, US
Carl June - Merion Station PA, US
Bruce Levine - Cherry Hill NJ, US

A61K039/395, C12N005/08

435/372000, 424/144100

A method is provided for producing a population of substantially purified CD4 Th2 lymphocytes. The method includes stimulating a population of substantially purified CD4 T cells isolated from a subject by contacting the population with an immobilized anti-CD3 monoclonal antibody and an immobilized antibody that specifically binds to a T cell costimulatory molecule in the presence of a Th2 supportive environment to form a stimulated population of T cells. Purified populations of Th2 cells are disclosed herein, as are methods for their use. For example, substantially purified CD4 Th2 lymphocytes can be used to treat graft-versus-host-disease, tumors, and autoimmune disorders.